Worldwide Study Finder

Phase 2Not yet recruitingINTERVENTIONAL

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

ClinicalTrials.gov · NCT06732245 · Registry updated: 2026-03-27

Condition / research focus: Obesity and Overweight
Sponsor: Biomed Industries, Inc.
Countries with listed sites: Australia · New Zealand · United States
Registry dates and results: Start: 2026-08-15. Completion: 2027-12-15 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NA-931 (drug) — also listed as: Tirzepatide placebo
Tirzepatide (drug) — also listed as: NA-931 Placebo
Tirzepatide (drug) — also listed as: NA-931 Placebo
NA-931 (drug)
NA-931 (drug) — also listed as: Tirzepatide
NA-931 (drug) — also listed as: Tirzepatide
NA-931 150 mg + no Tirzepatide (drug)
NA-931 (drug) — also listed as: Tirzepatide
NA-931 (drug) — also listed as: Tirzepatide

Where the study takes place — 17 listed sites

Phase 3CompletedINTERVENTIONAL

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

ClinicalTrials.gov · NCT06047548 · Registry updated: 2026-03-25

Condition / research focus: Overweight; Obesity
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2023-09-20. Completion: 2026-01-20 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 20 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Cahaba Research - Pelham
Pelham, Alabama, United States
Site recruitment: Not reported
Velocity Clinical Research, Westlake
Los Angeles, California, United States
Site recruitment: Not reported
Southern California Dermatology, Inc.
Santa Ana, California, United States
Site recruitment: Not reported
Encompass Clinical Research
Spring Valley, California, United States
Site recruitment: Not reported
New Horizon Research Center
Miami, Florida, United States
Site recruitment: Not reported
Oviedo Medical Research
Oviedo, Florida, United States
Site recruitment: Not reported
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, United States
Site recruitment: Not reported
East-West Medical Research Institute
Honolulu, Hawaii, United States
Site recruitment: Not reported
Rocky Mountain Clinical Research
Idaho Falls, Idaho, United States
Site recruitment: Not reported
Asha Clinical Research - Munster
Hammond, Indiana, United States
Site recruitment: Not reported
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Site recruitment: Not reported
L-MARC Research Center
Louisville, Kentucky, United States
Site recruitment: Not reported
Prime Health and Wellness/SKYCRNG
Fayette, Mississippi, United States
Site recruitment: Not reported
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Site recruitment: Not reported
WR-Clinsearch, LLC
Chattanooga, Tennessee, United States
Site recruitment: Not reported
The University of Texas Health Science Center at Houston
Bellaire, Texas, United States
Site recruitment: Not reported
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Site recruitment: Not reported
Southern Endocrinology Associates
Mesquite, Texas, United States
Site recruitment: Not reported
Pinnacle Clinical Research
San Antonio, Texas, United States
Site recruitment: Not reported
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay

ClinicalTrials.gov · NCT07492563 · Registry updated: 2026-03-25

Condition / research focus: Obesity; Type 2 Diabetes Mellitus; Overweight With Comorbidities
Sponsor: LABORATORIOS INDUFAR
Countries with listed sites: Paraguay
Registry dates and results: Start: 2026-03. Completion: 2027-10 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (T.G.) (drug)

Where the study takes place — 1 listed sites

Endocrinology Unit, UNA, Py
Asunción, Paraguay
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes

ClinicalTrials.gov · NCT07491133 · Registry updated: 2026-03-24

Condition / research focus: Type 1 Diabetes Mellitus
Sponsor: Institut de Recherches Cliniques de Montreal
Countries with listed sites: Canada
Registry dates and results: Start: 2026-03. Completion: 2027-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Environmental Temperature Exposure (other) — also listed as: Temperature Stress Testing, Thermal Exposure Protocol, Environmental Chamber Study, Ambient Temperature Intervention, Temperature-Insulin Absorption Study

Where the study takes place — 1 listed sites

Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Tirzepatide to Slow Biological Aging

ClinicalTrials.gov · NCT07220473 · Registry updated: 2026-03-24

Condition / research focus: Aging; LONGEVITY 1
Sponsor: The University of Texas Medical Branch, Galveston
Countries with listed sites: United States
Registry dates and results: Start: 2026-02-27. Completion: 2028-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Zepbound (drug) — also listed as: Tirzepatide

Where the study takes place — 1 listed sites

University of Texas Medical Branch
Galveston, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

ClinicalTrials.gov · NCT06037252 · Registry updated: 2026-03-23

Condition / research focus: Type 2 Diabetes; Obesity
Sponsor: Eli Lilly and Company
Countries with listed sites: Argentina · Mexico · Turkey (Türkiye) · United States
Registry dates and results: Start: 2023-09-21. Completion: 2026-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 40 listed sites

Medical Advancement Centers of Arizona
Phoenix, Arizona, United States
Site recruitment: Not reported
John Muir Physician Network Research Center
Concord, California, United States
Site recruitment: Not reported
Care Access - Sacramento
Sacramento, California, United States
Site recruitment: Not reported
Care Access - Aurora
Aurora, Colorado, United States
Site recruitment: Not reported
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Site recruitment: Not reported
Retreat Medical Research
Miami, Florida, United States
Site recruitment: Not reported
American Research Centers of Florida
Pembroke Pines, Florida, United States
Site recruitment: Not reported
Alta Pharmaceutical Research Center
Norcross, Georgia, United States
Site recruitment: Not reported
AGILE Clinical Research Trials, LLC
Sandy Springs, Georgia, United States
Site recruitment: Not reported
Northwestern University
Chicago, Illinois, United States
Site recruitment: Not reported
Qualmedica Research, LLC
Evansville, Indiana, United States
Site recruitment: Not reported
Integrated Clinical Trial Services, Inc.
West Des Moines, Iowa, United States
Site recruitment: Not reported
Accellacare - Wilmington - 1917 Tradd Court
Wilmington, North Carolina, United States
Site recruitment: Not reported
Velocity Clinical Research, Mt. Auburn
Cincinnati, Ohio, United States
Site recruitment: Not reported
Summit Headlands
Portland, Oregon, United States
Site recruitment: Not reported
Clinical Research Associates Inc
Nashville, Tennessee, United States
Site recruitment: Not reported
Juno Research
Houston, Texas, United States
Site recruitment: Not reported
Southern Endocrinology Associates
Mesquite, Texas, United States
Site recruitment: Not reported
Charlottesville Medical Research
Charlottesville, Virginia, United States
Site recruitment: Not reported
Northwest Clinical Research Center
Bellevue, Washington, United States
Site recruitment: Not reported
CEDIC
CABA, Buenos Aires, Argentina
Site recruitment: Not reported
Consultorio de Investigación Clínica EMO SRL
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
Centro Médico Viamonte
Buenos Aires, Buenos Aires F.D., Argentina
Site recruitment: Not reported
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Buenos Aires F.D., Argentina
Site recruitment: Not reported
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
Site recruitment: Not reported
Centro de Investigacion Cardiovascular y Metabólica
Tijuana, Estado de Baja California, Mexico
Site recruitment: Not reported
Virgen Cardiovascular Research SC
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported
Cryptex Investigación Clínica S.A. de C.V.
Cuauhtémoc, Ciudad de México, Mexico City, Mexico
Site recruitment: Not reported
Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
Mexico City, Mexico City, Mexico
Site recruitment: Not reported
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares
Ciudad Madero, Tamaulipas, Mexico
Site recruitment: Not reported
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Kadıköy, Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
Baskent Universitesi Adana Dr. Turgut Noyan Uygulama ve Arastirma Merkezi
Adana, Turkey (Türkiye)
Site recruitment: Not reported
Akdeniz Universitesi Hastanesi
Antalya, Turkey (Türkiye)
Site recruitment: Not reported
Uludag Universitesi
Bursa, Turkey (Türkiye)
Site recruitment: Not reported
Dicle Üniversitesi
Diyarbakır, Turkey (Türkiye)
Site recruitment: Not reported
Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi
Gaziantep, Turkey (Türkiye)
Site recruitment: Not reported
Acibadem Universitesi Atakent Hastanesi
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
Marmara Universitesi Pendik Egitim Arastirma Hastanesi
Istanbul, Turkey (Türkiye)
Site recruitment: Not reported
Ondokuz Mayıs Universitesi
Samsun, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4Not yet recruitingINTERVENTIONAL

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

ClinicalTrials.gov · NCT07483801 · Registry updated: 2026-03-19

Condition / research focus: Cardiovascular Diseases
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2026-03. Completion: 2028-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

semaglutide (drug)
Tirzepatide (drug)

Where the study takes place — 1 listed sites

Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

ClinicalTrials.gov · NCT07481747 · Registry updated: 2026-03-19

Condition / research focus: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Sponsor: Hudson Biotech
Countries with listed sites: China
Registry dates and results: Start: 2026-02-02. Completion: 2028-03-17 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Placebo (drug)
Reduced-calorie diet (behavioral)

Where the study takes place — 1 listed sites

Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

ClinicalTrials.gov · NCT05119179 · Registry updated: 2026-03-17

Condition / research focus: PreDiabetes
Sponsor: The University of Texas Health Science Center, Houston
Countries with listed sites: United States
Registry dates and results: Start: 2021-11-22. Completion: 2026-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic

Where the study takes place — 1 listed sites

UTHealth Clinical Research Unit (CRU) at UT Brownsville
Brownsville, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

ClinicalTrials.gov · NCT07207148 · Registry updated: 2026-03-17

Condition / research focus: Multiple Sclerosis
Sponsor: Northwestern University
Countries with listed sites: United States
Registry dates and results: Start: 2025-11-15. Completion: 2028-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug) — also listed as: Glucagon-like peptide-1, GLP-1 Agonist
Ocrelizumab (US) (drug) — also listed as: Ocrevus

Where the study takes place — 1 listed sites

Northwestern Memorial Hospital
Chicago, Illinois, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

ClinicalTrials.gov · NCT06671587 · Registry updated: 2026-03-17

Condition / research focus: Type 2 Diabetes (T2D)
Sponsor: Sanofi
Countries with listed sites: China
Registry dates and results: Start: 2024-12-10. Completion: 2026-09-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

iGlarLixi (insulin glargine/lixisenatide) (drug) — also listed as: SOLIQUA®
Gla-100 (insulin glargine) (drug) — also listed as: LANTUS®

Where the study takes place — 1 listed sites

Investigational Site Number: 1560001
Beijing, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

ClinicalTrials.gov · NCT07195994 · Registry updated: 2026-03-16

Condition / research focus: Prediabetes / Type 2 Diabetes
Sponsor: QuickSilver Scientific
Countries with listed sites: Canada
Registry dates and results: Start: 2026-02-05. Completion: 2026-09 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AMPK Charge+® (dietary_supplement)
AMPK Charge+® with semaglutide (dietary_supplement)

Where the study takes place — 1 listed sites

KGK Science Inc.
London, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

ClinicalTrials.gov · NCT06252493 · Registry updated: 2026-03-12

Condition / research focus: Crohn Disease
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2023-12-19. Completion: 2029-12-19 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Radiotracer Injection (drug)
Contrast Media, Magnetic Resonance (drug)
Blood Draw (diagnostic_test)
Glucagon (drug)
Imaging (diagnostic_test)
Oral contrast media application (drug)

Where the study takes place — 1 listed sites

Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School
Charlestown, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

ClinicalTrials.gov · NCT07467447 · Registry updated: 2026-03-12

Condition / research focus: Obesity
Sponsor: Hudson Biotech
Countries with listed sites: China
Registry dates and results: Start: 2026-02-15. Completion: 2028-02-17 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Retatrutide (LY3437943) (drug)
Placebo (drug)
Standardized diet and physical activity counseling throughout the study. (behavioral)

Where the study takes place — 1 listed sites

Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

ClinicalTrials.gov · NCT06246799 · Registry updated: 2026-03-10

Condition / research focus: Type 2 Diabetes (Adult Onset)
Sponsor: The University of Texas Health Science Center at San Antonio
Countries with listed sites: United States
Registry dates and results: Start: 2024-11-07. Completion: 2029-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: Mounjaro
Pioglitazone (drug) — also listed as: Actos
Sitagliptin (drug) — also listed as: Januvia
Metformin HCI XR (drug) — also listed as: Extended Release Metformin

Where the study takes place — 2 listed sites

University Health System Texas Diabetic Institute
San Antonio, Texas, United States
Site recruitment: Recruiting
UT Health Science Center
San Antonio, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4RecruitingINTERVENTIONAL

Effects of GH and Lirglutide on AgRP

ClinicalTrials.gov · NCT05681299 · Registry updated: 2026-03-04

Condition / research focus: Healthy; Growth Hormone Deficiency
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2023-05-01. Completion: 2028-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

growth hormone and lirglutide (drug)
growth hormone (drug)
liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center
New York, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Transformative Research in Diabetic Nephropathy 2.0

ClinicalTrials.gov · NCT07444203 · Registry updated: 2026-03-02

Condition / research focus: Diabetic Nephropathies; Kidney Diseases; Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Sponsor: University of Pennsylvania
Countries with listed sites: United States
Registry dates and results: Start: 2025-11-12. Completion: 2028-11-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) (drug) — also listed as: SGLT2 inhibitors
Renin-angiotensin-aldosterone system blockade (drug)
Glucagon-like peptide-1 receptor agonists (GLP 1 RA) (drug) — also listed as: GLP-1 receptor agonists
Mineralocorticoid Receptor Antagonists(MRAs) (drug) — also listed as: MRAs

Where the study takes place — 1 listed sites

Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity

ClinicalTrials.gov · NCT07304141 · Registry updated: 2026-02-27

Condition / research focus: Obesity (Disorder); Child Obesity
Sponsor: Göteborg University
Countries with listed sites: Sweden
Registry dates and results: Start: 2023-12-20. Completion: 2025-12-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide 3 mg (Saxenda) (other)

Where the study takes place — 1 listed sites

the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.
Gothenburg, Sweden
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

ClinicalTrials.gov · NCT06027567 · Registry updated: 2026-02-27

Condition / research focus: Idiopathic Intracranial Hypertension; Intracranial Pressure; Obesity; Pseudotumor Cerebri Syndrome; Papilledema; Weight Loss
Sponsor: Rigmor Højland Jensen
Countries with listed sites: Denmark
Registry dates and results: Start: 2022-09-02. Completion: 2025-10-28 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Ozempic, Wegovy
Very Low Calorie Diet (dietary_supplement)
Dietician counselling (behavioral)

Where the study takes place — 2 listed sites

Headache clinic, Department of Neurology, Odense University Hospital
Odense, Odense, Denmark
Site recruitment: Not reported
Danish Headache Center, Department of Neurology, Rigshospitalet
Glostrup Municipality, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis

ClinicalTrials.gov · NCT07439536 · Registry updated: 2026-02-27

Condition / research focus: Liver Cirrhosis With Diabetes
Sponsor: Kafrelsheikh University
Countries with listed sites: Egypt
Registry dates and results: Start: 2024-07-01. Completion: 2025-10-01 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Sitagliptin (Januvia) (drug)
Sitagliptin (JANUVIA®) (drug)
Sitagliptin (JANUVIA®) (drug)
Sitagliptin (JANUVIA®) (drug)
Duloxetine (60 mg) once daily (drug)
Duloxetine 30mg once daily (drug)

Where the study takes place — 1 listed sites

Kafr El-Sheikh University
Cairo, Kafrelsheikh, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Explore the world’s study registries

Worldwide

Africa

Americas

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay

Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes

Tirzepatide to Slow Biological Aging

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Effects of GH and Lirglutide on AgRP

Transformative Research in Diabetic Nephropathy 2.0

Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity

The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis

Asia

Middle East

Europe

Oceania